Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

This review is dedicated to the memory of Dr. Karen T. Liby, who passed away during the final editing of the manuscript. During her academic career, Karen made numerous extensive contributions to the pharmacology of Nrf2 activators, particularly to the preclinical development of the cyanoenone trite...

Descripción completa

Detalles Bibliográficos
Autores: Cuadrado, Antonio, Cazalla, Eduardo, Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, Raquel, Grochot-Przeczek, A., Hayes, J. D., Kensler, T. W., León, Rafael, Liby, K. T., López, M. G., Manda, Gina, Shivakumar, A. K., Hakomäki, H., Moerland, J. A., Rojo, Ana I., Sykiotis, G. P., Taguchi, K., Valverde, Ángela M., Yamamoto, M., Levonen, A. L.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/388245
Acceso en línea:http://hdl.handle.net/10261/388245
Access Level:acceso abierto
Palabra clave:KEAP1
NRF2 diseasome
GSK-3β-TrCP
Drug repurposing
Descripción
Sumario:This review is dedicated to the memory of Dr. Karen T. Liby, who passed away during the final editing of the manuscript. During her academic career, Karen made numerous extensive contributions to the pharmacology of Nrf2 activators, particularly to the preclinical development of the cyanoenone triterpenoids as multifunctional agents for prevention and treatment of chronic disease. Karen’s untimely passing is a huge loss for the Nrf2 community worldwide. Her kind personality and scientific rigour will be greatly missed.

Similares en LA Referencia